Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 16, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 2,600,000 ordinary shares.
- Repurchase Price: 1,074.92 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 8.98% of total voting rights).
- Shares in Issue: 5,392,391,440 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,600,000 shares on April 16, 2008. Consequently, the number of shares held in Treasury increased to 484,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard regulatory compliance with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the share repurchase (2,600,000 shares at 1,074.92 pence each).
- Confirm the updated total voting rights denominator (5,392,391,440 shares) for disclosure threshold calculations.
- Note that the repurchased shares were cancelled, reducing the total issued share count.
- Recognize that this filing does not contain quarterly or annual financial results.